原创：纽约群体免疫的可能性， 质询为什么福齐无能瞎说，质询为什么纽约敢在第一波就实行全体免疫？质询为甚在累累尸骨之上，明明已经达成了群体免疫，还要散布恐怖？

[lindamy]

说福奇杀人不是政治是科学？说总统失职就是政治了？

就和总统说FDA，CDC严格审核就是政治，他声称可以否决医疗机构就是科学一样。

 

[贵圈]

总统在科学家误导下，做出错误的指向，已经明摆着了！美国的结构设计，是总统很难为所欲为。你说呢？

而所有这些机构罔顾事实，罔顾逻辑。推行杀人政策，不是吗？

总统已经尽力，比如封闭中国航班，全球第一，在内部外部专家联手强力抵制的情况下，遵循逻辑，遵循基本的常识。领导能力！

结果证明，

福齐一错再错错到小学生都明白的的事儿，他都能错！
川普在福齐一再误导，和阻碍正确行动的背景下，利用总统的常识逻辑，做到了他能做到的最大努力。

没错吧。

再一次说，这楼不管政治，我在批评错误的“科学”论述。强烈谴责这类专家的杀人本质！

跟政治，跟选举，我不愿沾边。

 

[lindamy]

总统在科学家误导下，做出错误的指向，已经明摆着了！美国的结构设计，是总统很难为所欲为。你说呢？

而所有这些机构罔顾事实，罔顾逻辑。推行杀人政策，不是吗？

总统已经尽力，比如封闭中国航班，全球第一，在内部外部专家联手强力抵制的情况下，遵循逻辑，遵循基本的常识。领导能力！

结果证明，

福齐一错再错错到小学生都明白的的事儿，他都能错！
川普在福齐一再误导，和阻碍正确行动的背景下，利用总统的常识逻辑，做到了他能做到的最大努力。

没错吧。

再一次说，这楼不管政治，我在批评错误的“科学”论述。强烈谴责这类专家的杀人本质！

跟政治，跟选举，我不愿沾边。

实难苟同。

总统推行了不少杀人的政策，为了他的经济和竞选，也有部分正确的，也有些不在他权力范围，无能为力的，别把他打扮成个天真的小白兔，他要overrule FDA是被谁误导吗？他最为尽力是股市的各种新高。

你离政治和竞选有多远表现得很清楚。

 

[贵圈]

1。经济不仅仅是为了他，你要这么说，就是不公平了，美国经济崩塌，老百姓谁也跑不了。
2。选举，天经地义，他当然要为选举考虑。否则天诛地灭。但是，他考虑选举，也考虑的科学证据，也考虑了人民的生命。最后是一个平衡，这叫政治。
3。Overrule FDA的疫苗门槛？这就是政治决策。北京，莫斯科都没有门槛，直接推广。西方疫苗已经很谨慎了。面对世纪疫情。这是现代医学头一次需要在如此短的时间，对对如此复杂的病毒，和如此强烈的国际竞争。疫苗如果成熟，早推出一天，就是救命，就是救国。FDA划定门槛的高度，必须考虑科学以外的因素，考虑人道，考虑文明的危险，考虑国家的兴旺。很简单。FDA最终的疫苗门槛，必须是平衡的产物。作为个人，你必须知道，这个世界被技术官僚控制，你永远是他们的政治棋子。如果你不信任FDA的审核，大可以不打。但是别影响老乡他们打。
4。这里没有小白兔。但是，也不能做大灰狼。

不戴口罩，不封边，

大灰狼，要吃人的。

 

[向问天]

今天在这楼里发了几个技术贴。
以后不再发了。
骂人最爽。

 

[lindamy]

Coronavirus Antibodies Found in Small Portion of Americans, Study Says
Less than 10% of 28,000 dialysis patients in the U.S. had pathogen-fighting antibodies as of July, researchers found
By
Brianna Abbott
Updated Sept. 25, 2020 8:13 pm ET

Coronavirus Antibodies Found in Small Portion of Americans, Study Says

Less than 10% of 28,000 dialysis patients in the U.S. had the pathogen-fighting antibodies as of a July study, suggesting a high level of vulnerability in the general population.

www.wsj.com

 

[lindamy]

2 hr 1 min ago
Fewer than 10% in the US have antibodies to the novel coronavirus, study finds
From CNN’s Andrea Kane

A nationwide study of the blood of more than 28,000 people found that, as of July, approximately 9.3% in the United States had antibodies to the novel coronavirus. The numbers ranged from an average of 3.5% in the West to an average of 27% in the Northeast.

“This research clearly confirms that despite high rates of COVID-19 in the United States, the number of people with antibodies is still low and we haven’t come close to achieving herd immunity. Until an effective vaccine is approved, we need to make sure our more vulnerable populations are reached with prevention measures,” one of the study authors, Dr. Julie Parsonnet, a professor of medicine at Stanford University, said in a statement.

For the study, which was published Friday in The Lancet, researchers led by Stanford University’s Dr. Shuchi Anand, analyzed samples of plasma — a component of blood — from more than 28,500 patients receiving dialysis in July at approximately 1,300 facilities in 46 states run by one lab.

Why dialysis patients? “Patients receiving dialysis in the USA undergo routine monthly laboratory studies,” the researchers wrote, so there was no need for “considerable infrastructure and expense” to gather samples, nor were there other pandemic-related challenges.

Additionally, the risk factors for getting infected with coronavirus and for developing severe disease — including advanced age, non-White race, poverty and diabetes — “are the rule rather than the exception in the US dialysis population.”

The overall percent of people who were positive for antibodies among those sampled was 8%. Because dialysis patients aren’t representative of the US population, the researchers standardized the results with respect to age, sex, race and ethnicity, and region, to get an estimate of 9.3% seropositivity for the US adult population.

They found that there was a wide variation by state: seven states had 0% seropositivity, while New York, an early pandemic hotspot, topped the list with 33%.

The researchers were also able to see who was more likely to have antibodies. They found that, compared to the White population, residents of predominantly Black and Hispanic neighborhoods were two to three times more likely to be seropositive; people living in poorer areas were two times more likely; and those living in the most densely populated areas were 10 times more likely.

They also compared rates from their study with population case counts from Johns Hopkins University. From that, they estimated that only 9.2% of the patients with antibodies had been officially diagnosed by a test with Covid-19.

But, as the authors of an accompanying commentary point out, questions still remain about how long the antibodies last and how protective they are. Still, they wrote, studies like this one can help find answers if they can be repeated over time.

The study authors indicated the same. “A surveillance strategy relying on monthly testing of remainder plasma of patients receiving dialysis can produce unbiased estimates of SARS-CoV-2 spread inclusive of hard-to-reach, disadvantaged populations in the USA. Such surveillance can inform disease trends, resource allocation, and effectiveness of community interventions during the COVID-19 pandemic.”

 

[向问天]

2 hr 1 min ago
Fewer than 10% in the US have antibodies to the novel coronavirus, study finds
From CNN’s Andrea Kane

A nationwide study of the blood of more than 28,000 people found that, as of July, approximately 9.3% in the United States had antibodies to the novel coronavirus. The numbers ranged from an average of 3.5% in the West to an average of 27% in the Northeast.

For the study, which was published Friday in The Lancet, researchers led by Stanford University’s Dr. Shuchi Anand, analyzed samples of plasma — a component of blood — from more than 28,500 patients receiving dialysis in July at approximately 1,300 facilities in 46 states run by one lab.

Why dialysis patients? “Patients receiving dialysis in the USA undergo routine monthly laboratory studies,” the researchers wrote, so there was no need for “considerable infrastructure and expense” to gather samples, nor were there other pandemic-related challenges.

Additionally, the risk factors for getting infected with coronavirus and for developing severe disease — including advanced age, non-White race, poverty and diabetes — “are the rule rather than the exception in the US dialysis population.”

The overall percent of people who were positive for antibodies among those sampled was 8%. Because dialysis patients aren’t representative of the US population, the researchers standardized the results with respect to age, sex, race and ethnicity, and region, to get an estimate of 9.3% seropositivity for the US adult population.

They found that there was a wide variation by state: seven states had 0% seropositivity, while New York, an early pandemic hotspot, topped the list with 33%.

The researchers were also able to see who was more likely to have antibodies. They found that, compared to the White population, residents of predominantly Black and Hispanic neighborhoods were two to three times more likely to be seropositive; people living in poorer areas were two times more likely; and those living in the most densely populated areas were 10 times more likely.

They also compared rates from their study with population case counts from Johns Hopkins University. From that, they estimated that only 9.2% of the patients with antibodies had been officially diagnosed by a test with Covid-19.

But, as the authors of an accompanying commentary point out, questions still remain about how long the antibodies last and how protective they are. Still, they wrote, studies like this one can help find answers if they can be repeated over time.

The study authors indicated the same. “A surveillance strategy relying on monthly testing of remainder plasma of patients receiving dialysis can produce unbiased estimates of SARS-CoV-2 spread inclusive of hard-to-reach, disadvantaged populations in the USA. Such surveillance can inform disease trends, resource allocation, and effectiveness of community interventions during the COVID-19 pandemic.”

实际感染人数是确诊人数的10倍。
美国有1/4的人得过了。

 

[光放屁]

蒙圈，遍布欧美的第二波高峰有力的支持了楼主“已经达到群体免疫”的结论。

 

[贵圈]

是不是群体免疫，等着看吧。

 

[lindamy]

还等什么？法国一天都超过中国总数了，死亡数也在同步上涨。peak大叔严重误导。

 

[RareEarth]

现在的检测能力比第一个峰值高了不止10倍。感染数飙升反映的是检查能力。 随着已感染人群的扩大，传播会突然刹车。 不论有没有疫苗，川普在不在台上，明年1月新冠就会缓和。 让拜登捡了个便宜。只要号召戴口罩，就可以把功劳据为己有。如果聪明的化，就给米国人免费提供VD。也花不了多少钱。 不过新冠会和流感一样不断变异。不定期的会有新变异品种爆发。

 

[贵圈]

疫苗研发公司机构心里最清楚。这个新冠的结局和代价到底是什么。

 

[光放]

现在的检测能力比第一个峰值高了不止10倍。感染数飙升反映的是检查能力。 随着已感染人群的扩大，传播会突然刹车。 不论有没有疫苗，川普在不在台上，明年1月新冠就会缓和。 让拜登捡了个便宜。只要号召戴口罩，就可以把功劳据为己有。如果聪明的化，就给米国人免费提供VD。也花不了多少钱。 不过新冠会和流感一样不断变异。不定期的会有新变异品种爆发。

这个好办，感染人数除上检测人数就可以了。